Travere Therapeutics Profit Margin

The latest profit margin for TVTX is -11.22% as of June 2026. That compares with -50.64% in the prior-year period — up 77.8% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Travere Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TVTX's profit margin moved from -50.64% to -11.22% — a 77.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Travere Therapeutics's valuation or profitability profile.

Against Healthcare companies, TVTX currently prints -11.22% for profit margin, while the sector average sits near 13.89%. That is roughly 180.7% below the sector mean. Large gaps often invite a closer look at Travere Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Travere Therapeutics converts resources into returns. At -11.22%, TVTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -50.64% in the prior-year period — up 77.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TVTX's profit margin (-11.22%), review year-over-year change from -50.64%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.